Quanterix announces closing of public offering including exercise of underwriters’ option to purchase additional shares

Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $69.0 million.

J.P. Morgan Securities LLC and SVB Leerink LLC acted as joint book-running managers for the offering. Canaccord Genuity LLC acted as co-manager for the offering. Perella Weinberg Partners acted as independent capital markets advisor to Quanterix for the offering.

The public offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”). The final prospectus supplement and the accompanying prospectus relating to this offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov, copies of which can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6132 or by e-mail at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quanterix. (2019, October 29). Quanterix announces closing of public offering including exercise of underwriters’ option to purchase additional shares. News-Medical. Retrieved on November 08, 2024 from https://www.news-medical.net/news/20190813/Quanterix-announces-closing-of-public-offering-including-exercise-of-underwriters-option-to-purchase-additional-shares.aspx.

  • MLA

    Quanterix. "Quanterix announces closing of public offering including exercise of underwriters’ option to purchase additional shares". News-Medical. 08 November 2024. <https://www.news-medical.net/news/20190813/Quanterix-announces-closing-of-public-offering-including-exercise-of-underwriters-option-to-purchase-additional-shares.aspx>.

  • Chicago

    Quanterix. "Quanterix announces closing of public offering including exercise of underwriters’ option to purchase additional shares". News-Medical. https://www.news-medical.net/news/20190813/Quanterix-announces-closing-of-public-offering-including-exercise-of-underwriters-option-to-purchase-additional-shares.aspx. (accessed November 08, 2024).

  • Harvard

    Quanterix. 2019. Quanterix announces closing of public offering including exercise of underwriters’ option to purchase additional shares. News-Medical, viewed 08 November 2024, https://www.news-medical.net/news/20190813/Quanterix-announces-closing-of-public-offering-including-exercise-of-underwriters-option-to-purchase-additional-shares.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quanterix to release second quarter 2019 financial results and host conference call on Tuesday, August 6, 2019